Encelto is the first FDA-approved treatment for macular telangiectasia type 2. The cell therapy slows the loss of macular photoreceptors through continuous delivery of ciliary neurotrophic factor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback